Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope explains the design of the COSMIC-312 study in hepatocellular carcinoma (HCC) and speculates the potential this trial has.